We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+46.64%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$960M
AUM Growth
-$122M
Cap. Flow
-$259M
Cap. Flow %
-26.95%
Top 10 Hldgs %
38.43%
Holding
146
New
23
Increased
19
Reduced
38
Closed
47

Top Buys

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$25.5M
2
IMNM icon
Immunome
IMNM
+$14.6M
3
ACET icon
Adicet Bio
ACET
+$14.3M
4
EOLS icon
Evolus
EOLS
+$13.6M
5
OTLK icon
Outlook Therapeutics
OTLK
+$13.1M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$91.5M
2
IMGN
Immunogen Inc
IMGN
+$65.2M
3
LIAN
LianBio American Depositary Shares
LIAN
+$41.9M
4
AXSM icon
Axsome Therapeutics
AXSM
+$25.5M
5
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 98.03%
2 Technology 0.94%
3 Communication Services 0.51%
4 Real Estate 0.32%
5 Financials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VSTM icon
51
Verastem
VSTM
$610M
$6.39M 0.67%
541,514
-200,000
-27% -$2.31M
DSGN icon
52
Design Therapeutics
DSGN
$876M
$5.97M 0.62%
1,480,975
+300
+0% +$801
NKTX icon
53
Nkarta
NKTX
$172M
$5.95M 0.62%
550,000
– –
ONC
54
BeOne Medicines Ltd
ONC
$39.4B
$5.79M 0.6%
37,000
-48,000
-56% -$7.73M
NTLA icon
55
Intellia Therapeutics
NTLA
$1.67B
$5.5M 0.57%
200,000
– –
ENTA icon
56
Enanta Pharmaceuticals
ENTA
$400M
$5.24M 0.55%
300,000
– –
FATE icon
57
Fate Therapeutics
FATE
$326M
$5.14M 0.54%
700,000
– –
HRTX icon
58
Heron Therapeutics
HRTX
$92.9M
$5.12M 0.53%
1,850,000
– –
BCAB icon
59
BioAtla
BCAB
$5.74M
$5.07M 0.53%
29,482
-21,000
-42% -$2.61M
OKUR
60
OnKure Therapeutics
OKUR
$168M
$4.98M 0.52%
299,700
-33,300
-10% -$549K
META icon
61
Meta Platforms (Facebook)
META
$1.51T
$4.86M 0.51%
+10,000
New +$4.46M
BOLT icon
62
Bolt Biotherapeutics
BOLT
$7.78M
$4.79M 0.5%
171,000
-11,612
-6% -$269K
GPCR icon
63
Structure Therapeutics
GPCR
$3.78B
$4.29M 0.45%
+100,000
New +$4.22M
BCRX icon
64
BioCryst Pharmaceuticals
BCRX
$2.4B
$4.06M 0.42%
800,000
– –
IPSC icon
65
Century Therapeutics
IPSC
$361M
$3.76M 0.39%
900,000
-166,440
-16% -$704K
BLUE
66
DELISTED
bluebird bio
BLUE
$3.2M 0.33%
125,000
+40,000
+47% +$1.03M
QNCX icon
67
Quince Therapeutics
QNCX
$29.5M
$3.12M 0.33%
14,738
-1,362
-8% -$338K
EQC
68
DELISTED
Equity Commonwealth
EQC
$3.12M 0.32%
165,261
-134,739
-45% -$2.56M
LNTH icon
69
Lantheus
LNTH
$6.59B
$3.11M 0.32%
+50,000
New +$2.94M
GMAB icon
70
Genmab
GMAB
$19.5B
$2.99M 0.31%
+100,000
New +$2.94M
DFTX
71
Definium Therapeutics
DFTX
$6.12B
$2.82M 0.29%
+300,000
New +$1.71M
KNTE
72
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$2.6M 0.27%
977,626
-1,624,021
-62% -$4.02M
LONA
73
LeonaBio Inc
LONA
$72.1M
$2.34M 0.24%
85,272
-30,000
-26% -$952K
ADAP
74
DELISTED
Adaptimmune Therapeutics
ADAP
$2.28M 0.24%
1,443,619
-2,943,619
-67% -$3.55M
AMRN
75
Amarin Corp
AMRN
$303M
$2.23M 0.23%
125,000
-29,327
-19% -$626K
1 2
3
4 5

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Tang Capital Management held 146 positions worth $960M, down 11% from $1.08B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tang Capital Management withdrew a net $259M in Q1 2024, closing 47 positions and reducing 38 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $91.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Tang Capital Management opened a new position in Inhibrx, Inc. Common Stock worth $24.5M.

  • Tang Capital Management's largest Q1 2024 buy was Inhibrx, Inc. Common Stock: 700,000 shares worth $24.5M.
  • Tang Capital Management added most to Adicet Bio in Q1 2024, an estimated $14.3M increase.
  • Tang Capital Management's biggest Q1 2024 reduction was AnaptysBio, cutting an estimated $14.7M.
  • Tang Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $91.5M.
  • Tang Capital Management's ten largest holdings make up 38% of its $960M portfolio in Q1 2024.
  • Tang Capital Management opened 23 new positions and closed 47 in Q1 2024.
  • Tang Capital Management's portfolio value fell 11% quarter-over-quarter to $960M.

Based on Tang Capital Management's 13F filing for Q1 2024, filed 15 May 2024.